Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2 − breast cancer: Available evidence and clinical implications

Initially implemented in clinical practice for the treatment of locally advanced breast cancer (BC) patients, the use of neoadjuvant treatment has progressively increased over the last decades and is nowadays considered the standard of care for many early BC patients as well [1,2]. In this context, neoadjuvant chemotherapy (NCT) is widely used to downstage initially operable BCs, increasing the rates of conservative surgery [3]; however, it is well-known that the magnitude of response to NCT varies significantly according to breast cancer subtype.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Hot Topic Source Type: research